{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang Z"],"funding":["NCATS NIH HHS","NIGMS NIH HHS","NIH HHS"],"pagination":["1640-1656"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11363328"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(8)"],"pubmed_abstract":["Glioblastoma (GBM) is the most aggressive and frequently occurring type of malignant brain tumor in adults. The initiation, progression, and recurrence of malignant tumors are known to be driven by a small subpopulation of cells known as tumor-initiating cells or cancer stem cells (CSCs). GBM CSCs play a pivotal role in orchestrating drug resistance and tumor relapse. As a prospective avenue for GBM intervention, the targeted suppression of GBM CSCs holds considerable promise. In this study, we found that rocaglates, compounds which are known to inhibit translation <i>via</i> targeting of the DEAD-box helicase eIF4A, exert a robust, dose-dependent cytotoxic impact on GBM CSCs with minimal killing of nonstem GBM cells. Subsequent optimization identified novel rocaglate derivatives (rocaglat"],"journal":["ACS central science"],"pubmed_title":["Identification of Rocaglate Acyl Sulfamides as Selective Inhibitors of Glioblastoma Stem Cells."],"pmcid":["PMC11363328"],"funding_grant_id":["R35 GM118173","S10 OD028585","S10 OD026807","U01 TR002625"],"pubmed_authors":["Mishra AK","Thakare RP","Malonia SK","Li R","Chitale S","Huang S","Pelletier J","Fan AC","Zhu LJ","Green MR","Porco JA","Wang Z","Goldstein SI","Brown LE","Cencic R"],"additional_accession":[]},"is_claimable":false,"name":"Identification of Rocaglate Acyl Sulfamides as Selective Inhibitors of Glioblastoma Stem Cells.","description":"Glioblastoma (GBM) is the most aggressive and frequently occurring type of malignant brain tumor in adults. The initiation, progression, and recurrence of malignant tumors are known to be driven by a small subpopulation of cells known as tumor-initiating cells or cancer stem cells (CSCs). GBM CSCs play a pivotal role in orchestrating drug resistance and tumor relapse. As a prospective avenue for GBM intervention, the targeted suppression of GBM CSCs holds considerable promise. In this study, we found that rocaglates, compounds which are known to inhibit translation <i>via</i> targeting of the DEAD-box helicase eIF4A, exert a robust, dose-dependent cytotoxic impact on GBM CSCs with minimal killing of nonstem GBM cells. Subsequent optimization identified novel rocaglate derivatives (rocaglat","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-06-02T22:03:07.8Z","creation":"2025-04-05T12:31:35.828Z"},"accession":"S-EPMC11363328","cross_references":{"pubmed":["39220711"],"doi":["10.1021/acscentsci.4c01073"]}}